Global Chronic Refractory Cough (CRC) Epidemiology Forecast Report 2021-2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan - ResearchAndMarkets.com

·5 min read

The "Chronic Refractory Cough (CRC) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Chronic Refractory Cough (CRC) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Refractory Cough (CRC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Refractory Cough (CRC) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Chronic Cough, Gender-specific Prevalent Population of Chronic Cough, Prevalent Population of Chronic Refractory Cough (CRC), Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) and Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) in Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.

Chronic Refractory Cough (CRC) Detailed Epidemiology Segmentation

  • The total prevalent population of Chronic Cough in the 7 major markets was estimated to be 84,854,266 in 2020.

  • The prevalent population of CRC in the 7 major markets was estimated to be 17,600,264 in 2020.

  • The total diagnosed prevalent population of CRC in the 7 major markets was estimated to be 10,560,159 in 2020. In case of CRC patients in the United States, the diagnosed prevalent cases were 4,802,273 in 2020.

  • The diagnosed prevalent population of CRC in the 7 MM is expected to increase at a CAGR of 0.48% during the forecast period 2021-2030.

  • In the EU5 countries, the prevalent population of Chronic Cough was maximum in France with 8,799,771 cases followed by the United Kingdom with 8,682,007 cases in 2020. While, Spain accounted for the lowest diagnosed prevalent population of the indication with 5,708,813 cases in 2020.

  • As per this analysis, Japan had 683,935 diagnosed prevalent cases of CRC in 2020.

  • In the United States, the total prevalent cases of Chronic Cough comprised of 10,805,114 males and 29,213,828 females in 2020.

  • The total number of diagnosed prevalent cases of CRC in IPF patients was 106,801 in the United States, in 2020.

Scope of the Report

  • The report covers the descriptive overview of Chronic Refractory Cough (CRC), explaining its causes, signs and symptoms, pathophysiology.

  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Refractory Cough (CRC).

  • The report provides the segmentation of the disease epidemiology for the 7MM by Prevalent Population of Chronic Cough, Gender-specific Prevalent Population of Chronic Cough, Prevalent Population of Chronic Refractory Cough (CRC), Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) and Diagnosed Prevalent Population of Chronic Refractory Cough (CRC) in Idiopathic Pulmonary Fibrosis (IPF) patients.

Report Highlights

  • Ten Year Forecast of Chronic Refractory Cough (CRC)

  • 7MM Coverage

  • Total Diagnosed Prevalent Population of Chronic Refractory Cough (CRC)

  • The publisher has analysed prevalent population of Chronic cough and CRC in the 7MM for the study period of 2018-2030.

  • Diagnosed prevalence of CRC was also assessed, which suggests that the cases of CRC will increase during the forecast period of 2021-2030.

  • In addition, gener-specific prevalence of Chronic Cough was also assessed. As per the analysis, CRC is more prevalent in females than in males.

  • The report also encompasses another major segment, i.e., Diagnosed Prevalent Population of CRC in IPF patients, wherein the number of IPF patients suffering from CRC was calculated.

Analyst Comments

  • Various epidemiological studies on chronic cough are available in the US and European countries through which its prevalence has been estimated. However, the prevalent population for CRC has been derived from the prevalent patient pool of chronic cough in the 7 MM.

  • It is important to note that even though there is a shortage of detailed epidemiological studies on chronic cough and CRC in Japan, however, the publisher has referred to certain regional studies to understand the basis of the disease occurrence in the country.

  • Futhermore, IPF can be termed as a major contributor of CRC patient pool, therefore, the prevalence of CRC in IPF patients has also been estimated in this report.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Chronic Refractory Cough (CRC)?

  • What is the historical Chronic Refractory Cough (CRC) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

  • What would be the forecasted patient pool of Chronic Refractory Cough (CRC) at the 7MM level?

  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Refractory Cough (CRC)?

  • Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Refractory Cough (CRC) during the forecast period (2021-2030)?

  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Key Assessments

  • Patient Segmentation

  • Disease Risk and Burden

  • Risk of disease by the segmentation

  • Factors driving growth in a specific patient population

For more information about this report visit https://www.researchandmarkets.com/r/gmlabx

View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005609/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900